Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

Biopharma faces uncertainty in H2 2025 amid policy concerns and market challenges, with key healthcare conferences and ...

Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death for certain colorectal cancer ...

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...

Sanofi and Regeneron on Friday reported lackluster late-stage results for their drug candidate in a common lung condition, ...

Sinema has backed a bill advancing in the Arizona legislature that would include a $5 million grant to a neurological ...

Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a ...

The US Supreme Court will continue deciding whether to take up a pivotal case on state PBM regulation after the federal ...

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Midi Health, the virtual care company best known for providing hormone therapy for women in menopause, is expanding to ...

Sanofi partners in Vietnam, Almac hits £1B sales, Quadria raises $1.07B, CurifyLabs gets funding, BrainStorm signs with ...

Since Bernard Ravina's medical training in neurology in the '90s, there have been few new therapies that treat a movement ...